I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

AAIC 2023

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Jul 19 / Roche and Genentech
Observations on Biomarkers in Roche Abeta-targeting Monoclonal Antibody Trials
Roche has been involved in the development of anti-amyloid therapies for Alzheimer’s disease (AD) for nearly two decades. This presentation discusses the imaging, CSF and plasma biomarker data obtained during clinical trials evaluating crenezumab and gantenerumab, in sporadic AD and autosomal dominant AD.

Sign up or login to unlock the full suite of MEDICALLY features

Jul 19 / Roche and Genentech
Effect of age, body mass index and apolipoprotein e genotype on plasma biomarkers of amyloid pathology
This poster referes to the analysis done untder the blood-based biomarkers project to evaluate the clinical and demographic variables that affect the performance of the composite score.

Sign up or login to unlock the full suite of MEDICALLY features

Jul 17 / Roche and Genentech
The AD Workbench NeuroToolKit Application (NTKApp) suite of cloud-based tools for secure collaborative research in Alzheimer’s Disease
The poster refers to the NTKApp, a statistical analysis tool focused on fostering colaborationg for cohort validation and collaboration, completely hosted on the AD workbench.
02:15 PM
Duration 75mins Hall 5
GRADUATE I and II: Revisiting the Key Findings From Two Phase III Studies Evaluating the Efficacy and Safety of Subcutaneous Gantenerumab in Early Alzheimer’s Disease
Lane C, Smith J, Perry RJ, Grimmer T, Lansdall CJ, Voyle N, Delmar P, Bittner T, Klein G, Schwab D, Schneider A, Salloway S, Cummings JL, Baudler M, Fontoura P, Doody RS

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 75mins Hall 5
GRADUATE I and II: Subgroup analyses from two Phase III studies evaluating the efficacy and safety of subcutaneous gantenerumab in early Alzheimer’s disease (AD)
Thanasopoulou A, Lane C, Delmar P, Voyle N, Huang Z, Schwab D, Fox NC, Smith J, Doody RS

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 75mins Hall 5
GRADUATE I and II: Subgroup analysis and correlations of biomarkers
Bittner T, Belousov A, Lane C, Klein G, Tonietto M, Illiano V, Blennow K, Barkhof F, Smith J, Doody RS

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 75mins Elicium 2
A perspective on data sharing from potentially registrational trials
Sink KM, Narburgh L, Hu N, Tucker K, Doody RS

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:15 PM
Duration 75mins Elicium 2
Statistical innovations in the API ADAD Colombia trial: a randomized, double-blind, placebo-controlled, parallel-group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab
Hu N, Mackey H, Doody RS, Lopera F, Tariot PN, Reiman EM, Thomas RG, Langbaum JB, Sink KM

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:15 AM
Duration 75mins Hall 5
Observations on Biomarkers in Roche Abeta-targeting Monoclonal Antibody Trials
Doody RS

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar